Medication Overview
Benlysta (belimumab) is an injectable prescription medication used to treat systemic lupus erythematosus (SLE) and lupus nephritis in adults. It functions by targeting and inhibiting a specific protein called B-lymphocyte stimulator (BLyS), which contributes to the abnormal B cell activity in lupus.
Who Should Consider Benlysta? Benlysta is appropriate for adults who:
Infections may weaken your immune system, elevating your risk of infections. Immediately report any signs of infection, such as fever
- Have active systemic lupus erythematosus (SLE) despite receiving standard therapy.
- Are diagnosed with lupus nephritis and require additional treatment to manage the disease.
- Need a medication that specifically targets B-cell activity in lupus.
How is Benlysta Administered?
Benlysta can be administered in two ways:
- Intravenous (IV) Infusion: Administered by a healthcare professional in a clinical setting, typically every 2 to 4 weeks.
- Subcutaneous Injection: Self-administered weekly using a pre-filled syringe or autoinjector. Your healthcare provider will instruct you on how to perform the injection under the skin of your abdomen or thigh.
Important Information for Benlysta Users:
- How to Use: Follow your healthcare provider’s instructions for administering Benlysta, whether by infusion or injection.
- Storage: Keep Benlysta refrigerated. If using a pre-filled syringe or autoinjector, allow it to reach room temperature before injecting.
- Side Effects: Common side effects include nausea, diarrhea, fever, headaches, sore throats, and injection site reactions. Report any severe or unusual symptoms to your doctor.
- Monitoring: Regular medical check-ups and blood tests are recommended to monitor your health and the medication’s effects.
Medication Warnings
- Infections: Benlysta may weaken your immune system, elevating your risk of infections. Immediately report any signs of infection, such as fever, chills, or persistent cough, to your healthcare provider.
- Mental Health: There is a risk of depression, mood changes, and suicidal thoughts. Alert your healthcare provider if you experience these symptoms.
- Allergic Reactions: Seek immediate medical help if you experience symptoms like rash, itching, swelling, dizziness, or trouble breathing.
- Infusion Reactions: Some individuals may experience reactions during or after an IV infusion, such as headaches, nausea, and low blood pressure. Inform your healthcare provider if these symptoms occur.
- Cancer Risk: There is a potential increased risk of certain types of cancer. Discuss your medical history and risk factors with your healthcare provider.
Who Should and Shouldn’t Take Benlysta?
- Suitable Candidates:
- Adults with active SLE or lupus nephritis seeking specific B-cell targeted therapy.
- Unsuitable Candidates:
- Individuals with severe, active infections.
- Patients with a history of hypersensitivity to belimumab or any of the excipients in the formulation.
- Those with severe psychiatric conditions without proper medical supervision due to the risk of mental health side effects.
